Table 1 Patients` characteristics and treatment response
From: Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
A) Episodic migraine (n=26) | |||||
Age, y | 52.9 (SD 9.1) | Sex, female : male | 23 : 3 | ||
Before treatment, d | After 3 month, d | P-value | Change from baseline, d | 50% response, % | |
MMD (SD) | 9.42 (2.91) | 5.99 (5.43) | < 0.001 | -3.43 (SE 1.26) | 57.7 |
MHD (SD) | 10.40 (2.47) | 7.06 (5.46) | 0.001 | -3.33 (SE 1.17) | 46.2 |
AMD (SD) | 10.22 (4.69) | 5.74 (5.07) | <0.001 | -4.48 (SE 1.27) | 61.5 |
B) Chronic migraine (n=74) | |||||
Age, y | 45.8 (SD 12.9) | Sex, female : male | 59 : 15 | ||
MOH (before treatment), n | 49 | MOH (after 3 month), n | 26 | ||
Before treatment, d | After 3 month, d | P-value | Change from baseline, d | 50% response, % | |
MMD (SD) | 15.69 (6.64) | 10.97 (7.81) | <0.001 | -4.72 (SE 0.87) | 41.9 |
MHD (SD) | 21.27 (5.5) | 15.8 (8.9) | <0.001 | -5.47 (SE 0.86) | 32.4 |
AMD (SD) | 11.62 (6.14) | 8.86 (5.97) | <0.001 | -2.76 (SE 0.83) | 27.0 |